Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 17,647

Document Document Title
WO/2010/007788A1
Disclosed is a gap junction inhibitor which is more practically useful compared with carbenoxolone. Also disclosed is a novel glycyrrhetinic acid derivative. The glycyrrhetinic acid derivative is represented by general formula (1) or (2).  
WO/2010/009312A3
Disclosed herein are compositions and methods for treatment of muscle dysfunction (including sarcopenia) and other diseases involving skeletal musle, including age-related muscle dysfunction. In addition, the invention relates to therape...  
WO/2010/007972A1
The invention relates to the study on the synthesis of a novel indole derivative having a carbamoyl group, a ureide group and a substituted oxy group or a salt thereof, and also relates to the pharmacological activities of the derivative...  
WO/2010/008733A3
Solid forms of (lR,2S,3R>l-(2-(isoxazol-3-yl)-lH-imida2θl-4-yl)butane-l,2, 3,4- tetraol and hydrates thereof are disclosed, as well as compositions comprising them and methods of their use.  
WO/2010/007316A3
The invention relates to the novel products of formula (I): in which: Ra represents H, Hal, aryl or heteroaryl, which is optionally substituted; Rb represents H, Rc, -COORc-CO-Rc or -CO-NRcRd; where Rc represents alkyl, cycloalkyl, heter...  
WO/2010/006086A2
The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also pr...  
WO/2010/006086A3
The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also pr...  
WO/2010/004982A1
Disclosed are: a safe and highly effective ameliorating or therapeutic agent for dyslipidemia; and a method for utilizing the ameliorating or therapeutic agent. Specifically disclosed are: an ameliorating or therapeutic agent for dyslip...  
WO/2010/005565A3
The present invention relates, in general, to Glycogen Storage Disease and, in particular, to a method of treating Glycogen Storage Disease-type-III and to compounds and compositions suitable for use in such a method.  
WO/2010/004283A2
We disclose agents useful in the treatment of diseases or conditions that would benefit from improved muscle function and including pharmaceutical compositions and diagnostic tests for determining the predisposition of a subject, in part...  
WO/2010/005565A2
The present invention relates, in general, to Glycogen Storage Disease and, in particular, to a method of treating Glycogen Storage Disease-type-III and to compounds and compositions suitable for use in such a method.  
WO/2010/004283A3
We disclose agents useful in the treatment of diseases or conditions that would benefit from improved muscle function and including pharmaceutical compositions and diagnostic tests for determining the predisposition of a subject, in part...  
WO/2010/001869A1
Disclosed is a compound which is useful as a prophylactic or therapeutic agent for diabetes and hardly causes an adverse side effect such as increase in body weight, accumulation of adipocytes, and hypertrophy of the heart. Specifically ...  
WO/2010/001185A1
A compound of formula (I), wherein X is Cl or F or hydrates, solvates, or salts thereof for use treating of mGluR1 and mGluR5 receptor-mediated disorders.  
WO/2010/001990A1
Disclosed is a tetracyclic compound represented by formula (I), a pharmaceutically acceptable salt thereof, or the like. (In the formula (I), formula (A) represents a benzene ring or the like; X represents CH or a nitrogen atom; Q repres...  
WO/2009/154230A1
Disclosed are: a safe and highly effective prophylactic/ameliorating or therapeutic agent for NASH; and use of the agent. The prophylactic/ameliorating or therapeutic agent for NASH comprises a combination of at least one component sele...  
WO/2009/155056A3
The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, inclu...  
WO/2009/155056A2
The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, inclu...  
WO/2009/147125A1
The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing non alcoholic fatty liver diseases (NAFLD).  
WO/2009/147228A1
An extract obtainable by a method comprising the steps extracting Russian Tarragon with water or a mixture of water with up to 20% by volume of a C1 to C3 alcohol.  
WO/2009/147229A1
A product comprising a) Russian Tarragon (Artemisia dracunculus), an extract of Russian Tarragon or a derivative thereof b) a creatine and/or carnitine compound or derivative or precursor thereof.  
WO/2009/147831A1
Disclosed is a method for the treatment of a mental disorder, which is characterized by administering an effective amount of a pharmaceutical composition comprising 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol or a pharmaceutically acceptable...  
WO/2009/144481A2
A construct comprising a cell delivery peptide covalently attached to a biologically active compound suitable for delivery of said biologically active compound into cells, wherein optionally the cells are cardiac muscle, skeletal muscle,...  
WO/2009/144278A2
An enriched conglutin-γ protein extract from lupin seeds having a % by weight of conglutin-γ between 10 and 30%, or a conglutin-γ protein, or functional derivatives thereof for use as a medicament, as food integrator or diet supplemen...  
WO/2009/145238A1
Disclosed is a CD8-positive regulatory T cell which is more practical for an immune-related disease in an animal including a human body. A CD8-positive CXCR3-positive T cell is used as an immunomodulatory agent.  
WO/2009/145590A2
The present invention relates to a novel piperazine derivative or pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition for treating central nervous system diseases comprising an effecti...  
WO/2009/146033A2
The present invention provides novel genetic modifiers of SMN function. In particular, the present invention provides methods of treating spinal muscular atrophy (SMA) in a subject in need thereof by manipulating specific genes in the BM...  
WO/2009/144093A1
Hydroxytyrosol or olive juice containing hydroxytyrosol can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.  
WO/2009/145590A3
The present invention relates to a novel piperazine derivative or pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition for treating central nervous system diseases comprising an effecti...  
WO/2009/146033A3
The present invention provides novel genetic modifiers of SMN function. In particular, the present invention provides methods of treating spinal muscular atrophy (SMA) in a subject in need thereof by manipulating specific genes in the BM...  
WO/2009/144278A3
An enriched conglutin-γ protein extract from lupin seeds having a % by weight of conglutin-γ between 10 and 30%, or a conglutin-γ protein, or functional derivatives thereof for use as a medicament, as food integrator or diet supplemen...  
WO/2009/146310A1
This disclosure relates to deuterated Tizanidine, to compositions comprising the compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by- administering ...  
WO/2009/144093A8
Hydroxytyrosol or olive juice containing hydroxytyrosol can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.  
WO/2009/144481A3
A construct comprising a cell delivery peptide covalently attached to a biologically active compound suitable for delivery of said biologically active compound into cells, wherein optionally the cells are cardiac muscle, skeletal muscle,...  
WO/2009/141159A1
Compounds of formula (I): wherein R1, R2, R3, and n are as defined herein, are useful for the treatment or prophylaxis of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia.  
WO/2009/142195A1
Disclosed is a method for inducing/maintaining remission of an immune disease, which can reduce serious adverse side effects and stress in a patient. After the induction of remission of an immune disease with a biological substance or a ...  
WO/2009/142321A1
The present invention is related to study on synthesis of a novel thiophenediamine derivative having a urea structure and finding of a pharmacological action of the derivative. Specifically, the present invention provides a compound rep...  
WO/2009/139876A2
Muscle tissue regeneration is one of the most important homeostatic processes of adult skeletal muscle, which after development retains the capacity to regenerate in response to different type of stimuli, including a direct trauma or neu...  
WO/2009/140448A8
The present invention provides a compound of the Formula (I), or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; ...  
WO/2009/139361A1
Disclosed is a glucocorticoid receptor agonist composed of a compound represented by formula (1) or a salt thereof, which is a 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative having a substituted oxy group. A novel pharmacologi...  
WO/2009/137880A1
The invention provides a method of treating a disorder characterised by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological disea...  
WO/2009/137879A1
The invention provides a method of treatment of any disorder in which administration of angiogenin is beneficial wherein the angiogenin is administered orally. Particularly, the oral angiogenin does not require a carrier or excipient or ...  
WO/2009/140448A1
The present invention provides a compound of the Formula (I), or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; ...  
WO/2009/133905A1
Disclosed is a pharmaceutical composition for the treatment or prevention of a disease which can be prevented or treated through the inhibition of the activity of human FGF-23 protein. Specifically disclosed is a peptide comprising an am...  
WO/2009/133861A1
Disclosed is a cyclic amine compound useful as an androgen receptor modulator. [In formula (I), R1 represents a hydrogen atom, a halogen atom or the like; R2 represents a hydrogen atom, a halogen atom or the like; R3 represents a heteroc...  
WO/2009/131201A1
Disclosed are: a therapeutic agent for intermittent claudication, which comprises a tricyclic compound represented by formula (I) [wherein R1 represents a substituted or unsubstituted lower alkyl] or a pharmacologically acceptable salt t...  
WO/2009/129501A1
Disclosed herein are compounds, compositions, and methods for enhancing smooth muscle function in a subject by administration of soluble epoxide hydrolase inhibitors and for treating subjects with smooth muscle disorders including erecti...  
WO/2009/128481A1
Disclosed is a glucokinase activator which is useful as a pharmaceutical agent such as a prophylactic/therapeutic agent for diabetes, obesity and others. Specifically disclosed is a compound represented by formula (I) [wherein each symbo...  
WO/2009/128558A1
Disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof, which can be used as an activator for a PPAR. (In the formula, R1 and R2 independently represent a hydrogen atom, an alkyl group h...  
WO/2009/124693A1
The present invention relates to 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4- benzoquinone (idebenone) for treating and/or preventing respiratory illness associated with certain forms of muscular dystrophy.  

Matches 701 - 750 out of 17,647